Impact of CYP2C19 gene polymorphism and precise antiplatelet therapy on short-term prognosis in patients with mild cerebral infarction
Objective To explore the impact of CYP2C19 gene polymorphism and antiplatelet precision therapy on short-term prognosis in patients with mild cerebral infarction.Methods A total of 160 patients with mild ischemic stroke were in-cluded in the study.A randomized number table was used to divide the study participants into control group and gene testing group,with 80 cases in each group.The control group were given conventional treatment according to the guidelines,while the gene testing group were given individualized treatment based on CYP2C19 gene testing results.Results In the CYP2C19 gene,the proportion of ultra-fast metabolism was 2.56％,fast metabolism was 48.72％,moderate metabolism was 38.46％,and slow metabolism was 10.26％.Difference in NIHSS scores on admission between the two groups was not statis-tically significant(P＞0.05),but the difference in NIHSS scores after treatment between the two groups was statistically sig-nificant(P＜0.05).There was no statistically significant difference in ADL scores at admission(P＞0.05),but there was statistically significant difference in ADL scores after treatment(P＜0.05).Conclusion The application of precise seconda-ry prevention treatment of cerebral infarction based on pharmacogenomics in patients with mild cerebral infarction can more effectively improve neurological functions and daily living abilities.
CYP2C19clopidogrelmild cerebral infarctionneurological function
国家科技期刊平台
NSTL
万方数据
